BLAINJECTIONINJECTABLE
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
MVASI (bevacizumab-awwb) by Amgen is vascular endothelial growth factor-directed antibody interactions [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2017.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MVASI (bevacizumab-awwb) is a monoclonal antibody manufactured by Amgen that inhibits vascular endothelial growth factor (VEGF), a key driver of abnormal blood vessel formation in cancer and ocular diseases. As a biosimilar to the reference bevacizumab (Avastin), it provides an alternative treatment option for eligible patients across multiple oncology and ophthalmology indications. The drug works by binding to VEGF and blocking its interaction with endothelial growth factor receptors, thereby suppressing tumor angiogenesis and reducing pathological neovascularization. MVASI represents a cost-effective entry into the mature anti-VEGF market, competing directly with other VEGF inhibitors and newer biosimilar alternatives.
$0.0BPart D
Mechanism of Action
Vascular Endothelial Growth Factor-directed Antibody Interactions
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Started Jul 2024
450 enrolled
Metastatic Colorectal Cancer
A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis
Started Jun 2022
0Non Small Cell Lung Cancer
Career Relevance
MVASI creates opportunities for field sales representatives, specialty pharmacy account managers, and medical science liaisons focused on oncology and ophthalmology practices, though in a mature, price-competitive segment. Success in this role requires deep knowledge of comparative efficacy/safety data versus originator and competitor biosimilars, formulary negotiations, and payer reimbursement strategies. Currently, zero open positions are linked to MVASI in the database, suggesting stable commercial staffing or possible market contraction relative to competitive threats.
Worked on MVASI at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.